What is the clinical utility of cryptococcal antigen testing?

What is the clinical utility of cryptococcal antigen testing?

• A. Detects cryptococcal polysaccharide capsule antigen in CSF or serum; used for diagnosis and monitoring
• B. Detects beta-D-glucan in serum
• C. Detects cryptococcal polysaccharide capsule antigen in CSF or serum
• D. Detects only CSF antigen

Answer: (B)

The key idea is that cryptococcal antigen testing detects the polysaccharide capsule antigen of Cryptococcus directly in body fluids, most commonly CSF or serum. This test is highly useful because it provides a rapid and specific signal of cryptococcal infection, which is crucial for timely diagnosis and treatment decisions, especially in patients with advanced HIV/AIDS or other immune suppression. In practice, a positive antigen test in CSF strongly supports cryptococcal meningitis, while a positive test in serum can serve as a screening tool to detect cryptococcal infection before meningitis develops and to guide further evaluation or treatment. The assay can be applied to either CSF or serum, not just one compartment, and antigen levels (titers) can be followed over time to gauge response to therapy in some settings. Beta-D-glucan, by contrast, is a broader fungal marker used to screen for invasive fungal infections in general; it is not specific to cryptococcosis. That’s why it wouldn’t be the best description of the clinical utility of cryptococcal antigen testing.

The key idea is that cryptococcal antigen testing detects the polysaccharide capsule antigen of Cryptococcus directly in body fluids, most commonly CSF or serum. This test is highly useful because it provides a rapid and specific signal of cryptococcal infection, which is crucial for timely diagnosis and treatment decisions, especially in patients with advanced HIV/AIDS or other immune suppression. In practice, a positive antigen test in CSF strongly supports cryptococcal meningitis, while a positive test in serum can serve as a screening tool to detect cryptococcal infection before meningitis develops and to guide further evaluation or treatment. The assay can be applied to either CSF or serum, not just one compartment, and antigen levels (titers) can be followed over time to gauge response to therapy in some settings.

Beta-D-glucan, by contrast, is a broader fungal marker used to screen for invasive fungal infections in general; it is not specific to cryptococcosis. That’s why it wouldn’t be the best description of the clinical utility of cryptococcal antigen testing.